|
|
||||||||
Brief Communication |
Correspondence: 1 Corresponding Author: Miguel Angel Jiménez-Clavero, Departamento de Enfermedades Emergentes, Laboratorio Central de Veterinaria, Ctra. Algete, km 8, 28110, Algete (Madrid), Spain, e-mail: majimenez{at}mapya.es
| Abstract |
|---|
|
|
|---|
Key Words: Fluorogenic polymerase chain reaction probes real-time West Nile virus
West Nile virus (WNV) is a member of the Flavivirus genus, within the family Flaviviridae, belonging to the Japanese encephalitis group, such as Japanese encephalitis virus (JEV), Usutu virus (USUV), Saint Louis encephalitis virus (SLEV), and Murray Valley Fever virus (MVFV). Transmitted by mosquito bites, WNV affects a wide range of vertebrates, including mammals, birds, reptilians, and amphibians. Birds are considered the main reservoir host of WNV, and migratory birds play an important role in its spread.9 WNV can be pathogenic in both domestic and wild birds. Horses are also highly susceptible, and mortality in these animals can be observed in WNV outbreaks. Humans infected by WNV may develop a variety of symptoms, from a mild fever to more severe illness, including acute encephalitis, meningitis, and hepatitis, which can be fatal in a small percentage (<1%) of cases.
West Nile virus exhibits 2 genetically distinct evolutionary lineages. Whereas strains from lineage 2 have been exclusively found in Africa,2 strains belonging to lineage 1 are widely distributed, with 2 different sublineages, or clades: clade 1a, present in Africa, Europe, Asia, and America, where it was recently introduced, and clade 1b, also known as Kunjin variants, found in Oceania. The emergence and re-emergence of WNV in different parts of the world make it necessary to implement surveillance programs aimed at detecting circulating virus in a variety of samples, including mosquitoes, human and animal tissues, cerebrospinal fluid, serum, blood, and blood derivatives. The most widely used methodology for WNV detection is based on RT-PCR, for which a variety of methods, including nested4 and real-time RT-PCR6,8,12 have been described. Although highly sensitive, nested RT-PCR is slow, cumbersome, and likely to result in cross-contamination, which restrains this technique from application in surveillance programs, where the analysis of a high number of samples in a short period of time is required. Real-time RT-PCR (RRT-PCR) methodology overcomes these difficulties by achieving a high sensitivity with a faster turnaround time. This methodology relies upon fluorogenic 5'-nuclease (TaqMan) probes, molecular beacons, FRET probes, or SYBR green fluorescent dyes.1 Of these, TaqMan-based assays have become the most widely used real-time PCR methods for virus detection, because they are more specific than SYBR green-based assays, and, in addition, they use hybridization probes of shorter length than molecular beacons and FRET probes, increasing the likelihood of locating a suitable target sequence within a highly variable viral RNA genome. An improvement in TaqMan assays is the introduction of a minor groove binder (MGB), a 3'-labelling group that, in addition to acting as a quencher, increases the binding affinity between the probe and its target sequence,5 allowing the selection of shorter probe sequence targets. The current OIE (World Organization for Animal Health) manual references highly specific and very sensitive nested and real-time RT-PCR methods for the detection of WNV, although none of these methods has been designed to detect lineage 2 WNV.7 This paper addresses the issue of whether the use of TaqMan-MGB probes can improve the performance of the real-time fluorogenic RT-PCR assays currently available for WNV diagnosis by broadening the spectrum of detection of WNV variants, with no significant loss in sensitivity.
The primers and probe set were designed using the Primer Express (version 2.0.0) software,a directed to a highly conserved sequence within the 3'NC region of the WNV genome, which was chosen using multiple alignments of previous and recent WNV sequences (Table 1). A second TaqMan-MGB probe was included to detect lineage 2 isolates of WNV whose genomes differ in 2 nucleotide positions from that of lineage 1 (Table 1). Virus isolates analyzed in this study included 6 WNV isolates: WNV Eg101, (Egypt,1951); WNV DAK (strain Ar B 310, Central African Republic, 1967), WNV NY99 (strain 99-34940-31A, New York State, 1999), WNV ISR (Israel, 1950)b; and WNV MOR'03 (Morocco, 2003)c and 1 isolate of Usutu virus (USUV, strain SAAR 1776).d All viruses were grown in Vero cellse except WNV MOR'03, which was grown in the BSR clone of BHK-21 (baby hamster kidney) cells.f Viruses were titrated by a standard limiting dilution assay.10 The remaining viruses analyzed in this study, comprising WNV representatives of lineages 1a (isolate NY'99), 1b (Kunjin), 2 (B956 prototype strain), and other flaviviruses (Dengue virus and yellow fever virus), were supplied as plasma-diluted, lyophilized material, quantified by quantitative real-time RT-PCR, as part of an External Quality Assessment for West Nile Virus diagnosis performed in 2005 by the European Network of Emerging Viral Diseases (ENIVD).g Tenfold dilutions of the clarified infection supernatants of each virus, or 0.1-ml suspensions of the lyophilized infected plasma, were subjected to nucleic acid extraction using High Pure Viral (HPV) Nucleic Acid extraction kith following manufacturer's instructions. The TaqMan MGB-RRT-PCR was carried out using a commercial kit (QuantiTect Probe RT-PCRi). Briefly, 2 µl of isolated RNA was mixed with 12.5 µl of 2x QuantiTect Probe RT-PCR Master Mix, 0.625 µl of QuantiTect RT-mix, WNV-specific primers (WN-LCV-F1 and WN-LCV-R1, Table 1) at 0.4 µM final concentration, each of the fluorogenic TaqMan probes (WN-LCV-S1 and WN-LCV-S2, Table 1) at 0.25 µM final concentration, and RNase-free water up to 25 µl. Amplification conditions consisted of a first reverse-transcription step at 50°C for 30 minutes, followed by 15 minutes at 95°C ("hot start") and 45 cycles of 15 seconds at 95°C and 1 minute at 60°C. The reaction was carried out in Smart Cycler II equipment and software.j The same samples were analyzed in parallel with the TaqMan-RRT-PCR method described by Lanciotti et al.6 (3'NC primers and probe set), which uses TAMRA (tetramethylrhodamine) as a quencher, with minor modifications, using the Smart Cycler II equipment and software.
|
|
|
Surveillance programs must target all WNV variants likely to occur in a given area. Bearing in mind the potential of the RRT-PCR technology for high-throughput screening,11 the method described here constitutes a valuable tool for surveillance of West Nile virus circulation in areas where both WNV lineages can be expected. However, the method still needs further validation with field samples in order to assess its suitability for diagnosis.
| Acknowledgments |
|---|
| Sources and manufacturers |
|---|
|
|
|---|
a. Primer Express (version 2.0.0) software, Applied Biosystems, Branchburg, NJ. ![]()
b. WNV DAK (strain Ar B 310, Central African Republic, 1967), WNV NY'99 (strain 99-34940-31A), Usutu virus (Strain SAAR 1776): Center for Ecology and Hydrology (CEH), Oxford, UK. ![]()
c. WNV-ISR: Israel Institute for Biological Research, Ness-Ziona, Israel. ![]()
d. WNV MOR'03: Biopharma, Rabat, Morocco. ![]()
e. Vero cells (ATCC-CCL 81): American Type Culture collection, Manassas, VA. ![]()
f. BSR clone of BHK-21 cells: Biopharma, Rabat, Morocco. ![]()
g. WNV NY'99, WNV 1b (Kunjin), WNV B956 prototype strain, Dengue virus and yellow fever virus RNAs: European Network of Emerging Viral Diseases (ENIVD). ![]()
h. High Pure Viral (HPV) Nucleic Acid extraction kit, Roche Diagnostics, Indianapolis, IN. ![]()
i. QuantiTect Probe RT-PCR, QIAGEN, Valencia, CA. ![]()
j. Smartcycler II, Cepheid, Sunnyvale, CA. ![]()
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Aguero, C. Gomez-Tejedor, M. Angeles Cubillo, C. Rubio, E. Romero, and A. Jimenez-Clavero Real-time fluorogenic reverse transcription polymerase chain reaction assay for detection of African horse sickness virus J Vet Diagn Invest, May 1, 2008; 20(3): 325 - 328. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |